Kim S, Buecher B, Andre T, Jary M, et al. Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen
versus mDCF in patients with metastatic or unresectable locally advanced
recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II
SCARCE GERCOR trial. BMC Cancer 2020;20:352.
PMID: 32334548